Approved Therapies Benefits and Limitations

This section provides a balanced overview of currently approved treatments for polycythemia vera, including phlebotomy, hydroxyurea, and interferon. Phlebotomy is described as effective, accessible, and inexpensive, yet associated with frequent procedures, iron deficiency, and reduced quality of life. Hydroxyurea offers convenient oral administration and cytoreductive benefits, particularly for leukocytosis, but is limited by intolerance or resistance in a subset of patients. Interferon is highlighted for its potential to induce durable hematologic and molecular responses and possibly alter disease course. However, its use is constrained by injection requirements, autoimmune toxicity, and tolerability concerns. Faculty emphasize that none of these therapies are universally effective or appropriate for all patients. Treatment selection must consider comorbidities, symptom burden, patient preferences, and long term goals. The discussion reinforces that flexibility and individualized care are essential, particularly given the prolonged disease course and evolving therapeutic landscape.